Oncotarget

Reviews:

Apelin/APJ system: A key therapeutic target for liver disease

Shuang-Yu Lv, Binbin Cui, Wei-Dong Chen and Yan-Dong Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:112145-112151. https://doi.org/10.18632/oncotarget.22841

Metrics: PDF 672 views  |   HTML 1452 views  |   ?  


Abstract

Shuang-Yu Lv1, Binbin Cui1, Wei-Dong Chen1,3 and Yan-Dong Wang2

1Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Medicine, Henan University, Kaifeng, Henan, P. R. China

2State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China

3Key Laboratory of Molecular Pathology, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, Inner Mongolia, P. R. China

Correspondence to:

Yan-Dong Wang, email: ydwangbuct2009@163.com

Wei-Dong Chen, email: wdchen666@163.com

Keywords: apelin; APJ; liver; cirrhosis; fibrosis

Received: April 19, 2017    Accepted: November 11, 2017    Published: December 01, 2017

ABSTRACT

Apelin, a new bioactive peptide, was identified as an endogenous ligand for APJ (Angiotensin II receptor-like 1). Apelin and its receptor have an abundant distribution in central nervous system and peripheral tissues, including liver. Apelin/APJ has diverse physiological and pathological effects, including regulation of cardiovascular function, angiogenesis, fluid homeostasis and so on. Apelin/APJ system may act as a novel potential therapeutic target for liver disease. In this article, we review the role of apelin/APJ system in liver fibrosis, hepatitis, hepatic cirrhosis, liver injury and metabolic liver disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22841